New cancer drug trial seeks to boost immune system against tumors

NCT ID NCT05751798

Recruiting now Disease control Sponsor: OSE Immunotherapeutics Source: ClinicalTrials.gov ↗

Summary

This early-stage clinical trial is testing a new immunotherapy drug called OSE-279 in people with advanced solid tumors or lymphomas. The study has three parts: first finding the safest dose, then testing safety when combined with another drug for lung cancer, and finally measuring how well the combination shrinks tumors. The goal is to control cancer growth by helping the body's immune system fight the disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Antwerp University Hospital
NOT_YET_RECRUITING

Edegem, 11013, Belgium
Centre Eugène Marquis
COMPLETED

Rennes, 35000, France
Centre Léon Bérard
RECRUITING

Lyon, 69373, France
Hopital Saint Joseph
RECRUITING

Paris, 75014, France
Hospital Regional Universitario de Málaga
RECRUITING

Málaga, 2901, Spain
Institut Gustave Roussy
RECRUITING

Villejuif, 94805, France
Institut Jules Bordet
RECRUITING

Anderlecht, 1070, Belgium
Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta (IDIBGI)
RECRUITING

Girona, 17007, Spain
Institut de Cancerologie de l'Ouest
RECRUITING

Saint-Herblain, 44805, France
Oncopole
RECRUITING

Toulouse, 31059, France
University Hospital A Coruña Biomedical Research Institute (INIBIC)
RECRUITING

A Coruña, Spain

Conditions

Explore the condition pages connected to this study.

LYMPHOMA NSCLC (NON-SMALL CELL LUNG CANCER) SOLID ADVANCED TUMOR